

Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma – a meta-analysis of 2,596 trial patients

Niels Weinhold,¹ Hans J. Salwender,² David A. Cairns,³ Marc S. Raab,¹ George Waldron,⁴ Igor W. Blau,⁵ Uta Bertsch,¹ Thomas Hielscher,⁶ Gareth J. Morgan,⁷ Anna Jauch,⁸ Faith E. Davies,⁷ Mathias Hänel,⁹ Gordon Cook,¹⁰ Christoph Scheid,¹¹ Richard Houlston,² Hartmut Goldschmidt,^{1,12} Graham Jackson¹³ and Martin F. Kaiser^{4,14}

¹Department of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany; ²Asklepios Tumorzentrum Hamburg, AK Altona and AK St. Georg, Hamburg, Germany; ³Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds, UK; ⁴Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK; ⁵Medical Clinic, Charité University Medicine Berlin, Berlin, Germany; ⁶Division of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany; ⁷Perlmutter Cancer Center, NYU Langone Health, NY, USA; ⁸Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany; ⁹Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany; ¹⁰Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK; ¹¹Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany; ¹²National Center for Tumor Diseases (NCT), University Clinic Heidelberg, Heidelberg, Germany; ¹³Department of Haematology, University of Newcastle, Newcastle Upon Tyne, UK and ¹⁴Department of Haematology, The Royal Marsden Hospital, London, UK

Correspondence: NIELS WEINHOLD - niels.weinhold@med.uni-heidelberg.de

MARTIN F. KAISER - martin.kaiser@icr.ac.uk


doi:10.3324/haematol.2021.278888

SUPPLEMENTAL TABLES


Supplemental Table 1. Multivariate Cox-regression analysis including gain(1q) and individual R-ISS risk variables.

Variable	Study	PFS					OS				
		Coef	SE	P	I ²	P _{het}	Coef	SE	P	I ²	P _{het}
gain(1q)	HD4	0.34	0.15	0.02			0.50	0.18	0.006		
	MM5	0.56	0.12	<0.001			0.83	0.17	<0.001		
	MyXI	0.18	0.08	0.04			0.29	0.11	0.008		
	Meta	0.35	0.12	0.005	72	0.03	0.52	0.17	0.002	72	0.03
ISS II	HD4	0.30	0.16	0.06			0.56	0.21	0.008		
	MM5	0.42	0.14	0.002			0.70	0.22	0.002		
	MyXI	0.17	0.10	0.10			0.35	0.15	0.02		
	Meta	0.27	0.08	<0.001	11	0.32	0.48	0.11	<0.001	0	0.40
ISS III	HD4	0.52	0.17	0.003			0.79	0.23	<0.001		
	MM5	0.53	0.14	<0.001			1.07	0.22	<0.001		
	MyXI	0.44	0.11	<0.001			0.81	0.15	<0.001		
	Meta	0.48	0.08	<0.001	0	0.87	0.87	0.11	<0.001	0	0.56
t(4;14)	HD4	0.48	0.19	0.01			0.40	0.22	0.07		
	MM5	0.23	0.18	0.21			0.34	0.22	0.13		
	MyXI	0.54	0.13	<0.001			0.41	0.16	0.01		
	Meta	0.44	0.09	<0.001	4	0.35	0.39	0.11	<0.001	0	0.97
t(14;16)	HD4	0.04	0.43	0.93			0.02	0.52	0.97		
	MM5	0.70	0.29	0.02			0.82	0.36	0.02		
	MyXI	0.33	0.23	0.16			0.46	0.26	0.08		
	Meta	0.40	0.17	0.02	0	0.40	0.50	0.20	0.01	0	0.40
del(17p)	HD4	0.70	0.22	0.001			0.94	0.24	<0.001		
	MM5	0.39	0.17	0.02			0.65	0.21	0.002		
	MyXI	0.55	0.12	<0.001			0.86	0.15	<0.001		
	Meta	0.53	0.09	<0.001	0	0.50	0.82	0.11	<0.001	0	0.61
LDH > normal	HD4	0.20	0.17	0.24			0.36	0.20	0.07		
	MM5	0.29	0.13	0.03			0.09	0.19	0.63		
	MyXI	0.10	0.09	0.26			0.30	0.11	0.006		
	Meta	0.16	0.07	0.01	0	0.47	0.27	0.09	0.002	0	0.56

SUPPLEMENTAL FIGURES



Supplemental Fig. 1. Prognostic impact of gain and amplification of 1q21 in multiple myeloma. Kaplan-Meier plots for PFS landmarked from start of maintenance therapy for **A)** the thalidomide treatment arm of HD4, **B)** the bortezomib treatment arm of HD4, **C)** MM5 arms A1 and A2, which received lenalidomide for 2 years, and **D)** the lenalidomide maintenance arm of NCRI Myeloma XI, from maintenance randomization.



Supplemental Fig. 2. Prognostic impact of gain(1q) and the number of high risk markers in context of the R-ISS. A-B: Kaplan-Meier overlay plots demonstrate the impact of including gain(1q) as a risk marker in R-ISS, termed R-ISS-1q. Plots show PFS for R-ISS and for R-ISS-1q for **A)** GMMG and **B)** Myeloma XI. **C-D:** Kaplan-Meier plots are shown for PFS for GMMG (**C)** and Myeloma XI (**D)** patients according to the number of risk markers present in these patients, including gain(1q) and R-ISS markers del(17p), t(4;14), t(14;16) or LDH above upper limit of normal, respectively. **E-F:** Kaplan-Meier plots for PFS showing discrimination of high- and ultra-high-risk groups by including information on co-occurrence of risk markers, called multi-hit, for further sub-grouping of R-ISS-1q stage II and stage III tumors in **E)** GMMG and **F)** Myeloma XI.